All In Biotech

Drug Trial Radar · NCT06881836

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

A Phase II, 26-week, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of ONO-2020 in Patients With Mild to Moderate Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

260

Actual

Start

Apr 24, 2025

Primary completion

Jul 31, 2026

Study completion Sep 1, 2026

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.

Conditions

  • Alzheimer Disease

Interventions

  • ONO-2020Drug

    ONO-2020 group: Two ONO-2020 tablets will be orally administered once daily.

  • PlaceboDrug

    Placebo group: Two ONO-2020 placebo tablets will be orally administered once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity, and type of treatment emergent adverse events (TEAEs)Time frame: From baseline up to 26 weeks
  2. Clinically abnormal findings in Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: From baseline up to 26 weeks
  3. Change from baseline through week 26 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 12 (ADAS-cog 12) scoreTime frame: From baseline up to 26 weeks

Locations

80 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner Alzheimer's Institute (BAI)

    Phoenix, Arizona

  • Clinical Endpoints

    Scottsdale, Arizona

  • Banner Sun Health Research Institute

    Sun City, Arizona

  • Center for Neurosciences-Research

    Tucson, Arizona

  • Profound Research LLC at The Neurology Center of Southern California

    Carlsbad, California

  • Neurology Center of North Orange County

    Fullerton, California

  • Stanford University

    Palo Alto, California

  • Sunwise Clinical Research

    Walnut Creek, California

  • CenExel Rocky Mountain Clinical Research

    Englewood, Colorado

  • Brain Matters Research

    Delray Beach, Florida

  • Quantum Clinical Trials

    Miami Beach, Florida

  • Suncoast Clinical Research

    New Port Richey, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Charter Research - Orlando

    Orlando, Florida

  • Accel Research Sites - Brain and Spine Institute

    Port Orange, Florida

  • USF Health Byrd Alzheimer's Institute

    Tampa, Florida

  • ForCare Clinical Research

    Tampa, Florida

  • Charter Research - The Villages

    The Villages, Florida

  • Conquest Research LLC

    Winter Park, Florida

  • Sandhill Research, LLC d/b/a Accel Research Sites - NeuroStudies CRU

    Decatur, Georgia

  • CenExel iResearch, LLC

    Savannah, Georgia

  • Velocity Clinical Research, Boise

    Meridian, Idaho

  • Re:Cognition Health-Chicago

    Chicago, Illinois

  • Ascension Alexian Brothers Medical Center

    Elk Grove Village, Illinois

  • University of Kansas Medical Center

    Fairway, Kansas

  • Univ of Kentucky Sanders-Brown Center on Aging

    Lexington, Kentucky

  • Boston Clinical Trials

    Boston, Massachusetts

  • ActivMed Research

    Methuen, Massachusetts

  • Cleveland Clinic Lou Ruvo Center for Brain Health

    Las Vegas, Nevada

  • Vector Clinical Trials

    Las Vegas, Nevada

  • The Cognitive and Research Center of New Jersey

    Springfield, New Jersey

  • Advanced Memory Research Institute of NJ (CenExel AMRI)

    Toms River, New Jersey

  • Advanced Clinical Institute Inc.

    West Long Branch, New Jersey

  • University at Buffalo

    Buffalo, New York

  • The Feinstein Institutes for Medical Research

    Manhasset, New York

  • NYU Center for Cognitive Neurology

    New York, New York

  • AD-CARE; University of Rochester

    Rochester, New York

  • Stony Brook University Hospital

    Stony Brook, New York

  • New Hope Clinical Research

    Charlotte, North Carolina

  • Velocity Clinical Research at Raleigh Neurology

    Raleigh, North Carolina

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.